Cyclin-dependent kinase 4/6 inhibitors beyond progression in hormone receptor-positive, HER2-negative advanced breast cancer: a systematic review and meta-analysis (REIGNITE study)
Our results support the strategy of switching the CDK4/6i in the second-line setting and demonstrate persistent benefit even in patients with PIK3CA or ESR1 mutations.
Authors
- J L da Silva
- Felipe Batalini (ORCID: https://orcid.org/0000-0003-3354-308X)
- Andréia Cristina de Melo (ORCID: https://orcid.org/0000-0002-1201-4333)
- Brenda Ernst (ORCID: https://orcid.org/0000-0002-7292-3950)
- Luís Felipe Leite (ORCID: https://orcid.org/0009-0006-8347-1212)
- Maria João Gouveia (ORCID: https://orcid.org/0000-0003-3747-5520)
- Mariana Macambira Noronha (ORCID: https://orcid.org/0000-0003-0889-7425)
- Paolo Tarantino (ORCID: https://orcid.org/0000-0001-8686-0228)
- Valbert Oliveira Costa Filho (ORCID: https://orcid.org/0009-0003-2864-0966)
- Luiz F. Costa de Almeida (ORCID: https://orcid.org/0009-0008-3286-3333)
- Anelise Poluboiarinov Cappellaro (ORCID: https://orcid.org/0009-0001-1624-7556)
Institutions
- Universidade Federal Fluminense (BR)
- Universidade Federal do Ceará (BR)
- Dana-Farber Cancer Institute (US)
- Instituto Nacional de Câncer - INCA (BR)
Publication Details
- Journal
- ESMO Open
- Published
- 2025-10-01
- DOI
- https://doi.org/10.1016/j.esmoop.2025.105808
- Citations
- 2
- Primary Topic
- Advanced Breast Cancer Therapies
- Type
- article
- Field-Weighted Citation Impact
- 3.04